Gene Logic re-examines Organon candidates

Gene Logic has struck a deal with Organon to take a new look at discontinued drug programs in an effort to find new uses for them. Upon the discovery of any new therapeutic uses, both companies would become joint owners, with Gene Logic receiving a "success-based milestone" payment. Gaithersburg, MD-based Gene Logic has developed a drug repositioning program that takes discontinued or "deprioritized" drug candidates that have been advanced into Phase II and Phase III and examines them for alternative development paths. New drug discovery technologies can be used to find a new therapeutic target for compounds that have proven safety profiles.

- read the release for more

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.